7月30日,丹诺医药向港交所递交招股说明书,拟在港股主板上市。此次冲刺IPO,丹诺医药计划募集资金将主要用于核心产品的研究、开发、注册备案及商业化;其他候选产品的研发;建设自有生产工厂;运营资金等。丹诺医药成立于2013年,是一家专注于细菌感染及细菌代谢相关疾病领域的 创新药 研发公司。目前,公司已建立起一条包含七项创新资产的研发管线,涵盖多个具有潜力的治疗领域。然而,在创新药研发这条充满挑战的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.